This review concluded that gefitinib could not be recommended for frontline management of unselected patients with advanced non-small cell lung cancer. Evidence appeared to support the author's conclusion, but the lack of reporting of trial quality and review methods made it difficult to assess its reliability.
Authors' objectives
To evaluate the efficacy of gefitinib for patients with locally advanced or metastatic non-small cell lung cancer.
Searching
PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane Database of Systematic Reviews, and DARE were searched for peer-reviewed studies published in English. Search terms were reported, but search dates were not. Proceedings of the main oncology conferences and reference lists of primary studies and reviews were screened.
Study selection
Randomised controlled trials (RCTs) were eligible for inclusion if they evaluated the efficacy of gefitinib-based therapy in chemotherapy-naive patients with locally advanced or metastatic non-small cell lung cancer. Trials were also eligible if they compared gefitinib with placebo or no treatment in patients who had all been offered initial induction with chemoradiation or chemotherapy. The review assessed objective response rate, progression-free survival, overall survival and quality of life.
The included trials compared: gefitinib plus chemotherapy versus chemotherapy alone; gefitinib alone versus chemotherapy; and gefitinib plus best supportive care versus best supportive care alone. Chemotherapeutic agents were reported. Most included patients were male, smokers and non-Asian; many had non-adenocarcinoma non-small cell lung cancer. The median age per treatment group ranged from 57 to 76 years. The percentage of patients with stage IIIB cancer ranged from 15 to 55% and 67 to 84% had stage IV cancer. Trials included patients with known and unknown epidermal growth factor receptor status.
The author did not state how papers were selected for the review.
Assessment of study quality
The author did not state that validity was assessed.
Data extraction
Log hazard ratios (HR) and variances were extracted or calculated for each trial.
The author stated that data were checked and compared with the original publications, but did not state how many reviewers were involved in this process.
